Is micronized progesterone safer than synthetic progestins?

Whether micronized progesterone is the more appropriate choice compared with synthetic progestins depends on individual health factors that cannot be assessed through website content alone. According to current NAMS guidelines, micronized progesterone is a bioidentical hormone that is structurally identical to endogenous progesterone and may have a more favorable profile than certain synthetic progestins in specific clinical contexts. A prescriber should evaluate which progestogen is suitable based on a patient's complete medical history.

What "micronized progesterone" means

Micronized progesterone is bioidentical progesterone processed into fine particles to improve oral bioavailability. Both FDA-approved products (such as estradiol and micronized progesterone) and compounded preparations may contain bioidentical hormones. The term does not indicate superiority of one category over another. Per FDA-approved prescribing information, micronized progesterone is available as a regulated prescription product (Prometrium). It can also be prepared by compounding pharmacies when a clinician determines that a commercially available form does not meet a patient's needs. Compounded medications are not FDA-approved. They have not been reviewed by the FDA for safety, effectiveness, or quality. FDA-approved medications should be considered first when commercially available options meet patient needs.

How it differs from synthetic progestins

• Breast risk: According to the WHI long-term follow-up data, the combination of conjugated equine estrogen with medroxyprogesterone acetate was associated with an increased breast cancer signal, whereas estrogen-only therapy was not. According to current NAMS guidelines, observational data suggest that micronized progesterone combined with estradiol may carry a lower breast cancer signal compared with certain synthetic progestins, though long-term randomized trial data remain limited.
• Heart and clotting: Per published clinical guidelines, micronized progesterone appears to have a more neutral effect on coagulation markers than some synthetic progestins; however, individual cardiovascular risk must be assessed by a clinician before initiating any hormone therapy.
• Uterine protection: Per FDA-approved prescribing information, both micronized progesterone and synthetic progestins are indicated to protect the endometrium in women with a uterus who are receiving estrogen therapy.
• Mood and sleep: Per published clinical guidelines, some patients report improved sleep and mood with micronized progesterone compared with certain synthetic progestins, though responses vary and have not been uniformly confirmed in randomized controlled trials.
• Metabolic effects: According to current NAMS guidelines, micronized progesterone tends to have a more neutral effect on lipid and glucose metabolism compared with some androgenic synthetic progestins; individual metabolic risk factors should be reviewed with a prescriber.

When synthetic progestins are still used

According to ACOG, synthetic progestins remain clinically appropriate options for many patients, and certain formulations have a longer evidence base from large randomized trials. Current clinical practice considers both classes of progestogen, and the choice is individualized based on the patient's health history, tolerability, and therapeutic goals.

Clinical considerations

Per the Endocrine Society, the decision to use micronized progesterone versus a synthetic progestin should be made in consultation with a qualified prescriber who can weigh the available evidence against the individual patient's risk profile. Whether HRT is appropriate depends on individual health factors. A prescriber should determine the best approach based on a patient's complete medical history.